View Financial HealthRapid Dose Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Rapid Dose Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-3.3%자사주 매입 수익률총 주주 수익률-3.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 13Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 26, 2026Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 26, 2026.Reported Earnings • Jun 30Full year 2026 earnings released: CA$0.025 loss per share (vs CA$0.043 loss in FY 2025)Full year 2026 results: CA$0.025 loss per share (improved from CA$0.043 loss in FY 2025). Revenue: CA$2.77m (up 33% from FY 2025). Net loss: CA$3.39m (loss narrowed 37% from FY 2025). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.New Risk • Jun 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$871k free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CA$6.6m). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (CA$13.0m market cap, or US$9.15m). Minor Risk Revenue is less than US$5m (CA$2.8m revenue, or US$2.0m).New Risk • Mar 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$871k free cash flow). Negative equity (-CA$6.6m). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (CA$13.5m market cap, or US$9.87m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$2.8m revenue, or US$2.0m).Reported Earnings • Feb 01Third quarter 2026 earnings released: CA$0.009 loss per share (vs CA$0.011 loss in 3Q 2025)Third quarter 2026 results: CA$0.009 loss per share (improved from CA$0.011 loss in 3Q 2025). Revenue: CA$657.1k (up 31% from 3Q 2025). Net loss: CA$1.14m (loss narrowed 16% from 3Q 2025).New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Negative equity (-CA$5.9m). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$2.6m revenue, or US$1.9m). Market cap is less than US$100m (CA$19.0m market cap, or US$13.7m).Reported Earnings • Nov 02Second quarter 2026 earnings released: EPS: CA$0.01 (vs CA$0.009 loss in 2Q 2025)Second quarter 2026 results: EPS: CA$0.01 (up from CA$0.009 loss in 2Q 2025). Revenue: CA$672.9k (up 30% from 2Q 2025). Net loss: CA$825.5k (loss narrowed 25% from 2Q 2025).New Risk • Jul 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$965k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$965k free cash flow). Negative equity (-CA$5.3m). Earnings have declined by 6.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (CA$2.5m revenue, or US$1.8m). Market cap is less than US$100m (CA$25.2m market cap, or US$18.3m).Reported Earnings • Jul 29First quarter 2026 earnings released: CA$0.006 loss per share (vs CA$0.01 loss in 1Q 2025)First quarter 2026 results: CA$0.006 loss per share (improved from CA$0.01 loss in 1Q 2025). Revenue: CA$782.7k (up 96% from 1Q 2025). Net loss: CA$723.7k (loss narrowed 42% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.043 loss per share (vs CA$0.041 loss in FY 2024)Full year 2025 results: CA$0.043 loss per share (further deteriorated from CA$0.041 loss in FY 2024). Revenue: CA$2.09m (up 104% from FY 2024). Net loss: CA$5.40m (loss widened 26% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.공고 • Jun 30Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025.공고 • May 28Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in fundingRapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.공고 • May 27Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery TechnologyRapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$4.1m). Minor Risks Revenue is less than US$5m (CA$1.6m revenue, or US$1.1m). Market cap is less than US$100m (CA$21.8m market cap, or US$15.0m).공고 • Feb 19Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.Reported Earnings • Jan 29Third quarter 2025 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 3Q 2024). Revenue: CA$501.7k (up 115% from 3Q 2024). Net loss: CA$1.36m (loss widened 39% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공고 • Dec 11Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share.Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2024)Second quarter 2025 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2024). Revenue: CA$515.9k (up 46% from 2Q 2024). Net loss: CA$1.10m (loss widened 51% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.공고 • Oct 31+ 1 more updateRapid Dose Therapeutics Corp. announced that it has received CAD 0.548799 million in funding from Madison Partners CorporationOn October 30, 2024. the company has closed the final tranche of the transaction분석 기사 • Aug 22This Is Why Rapid Dose Therapeutics Corp.'s (CSE:DOSE) CEO Compensation Looks AppropriateKey Insights Rapid Dose Therapeutics' Annual General Meeting to take place on 28th of August Total pay for CEO Mark...New Risk • Jul 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.8m free cash flow). Negative equity (-CA$3.3m). Revenue is less than US$1m (CA$1.2m revenue, or US$852k). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$22.4m market cap, or US$16.2m).Reported Earnings • Jun 30Full year 2024 earnings released: CA$0.041 loss per share (vs CA$0.037 loss in FY 2023)Full year 2024 results: CA$0.041 loss per share (further deteriorated from CA$0.037 loss in FY 2023). Revenue: CA$1.02m (up 42% from FY 2023). Net loss: CA$4.31m (loss widened 13% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.공고 • Jun 27Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024.공고 • Mar 26Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing.Reported Earnings • Jan 30Third quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in 3Q 2023). Revenue: CA$233.8k (down 24% from 3Q 2023). Net loss: CA$981.1k (loss widened 68% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.공고 • Jan 20Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in fundingRapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent.New Risk • Jan 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$524k free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-CA$3.8m). Revenue is less than US$1m (CA$1.1m revenue, or US$826k). Minor Risks Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Market cap is less than US$100m (CA$18.0m market cap, or US$13.3m).Reported Earnings • Oct 31Second quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.007 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$353.2k (up 164% from 2Q 2023). Net loss: CA$730.7k (loss narrowed 20% from 2Q 2023).공고 • Sep 23Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of DirectorsRapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023.New Risk • Aug 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$3.2m). Revenue is less than US$1m (CA$897k revenue, or US$663k). Market cap is less than US$10m (CA$13.5m market cap, or US$9.95m).Reported Earnings • Jul 31First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.01 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.01 loss in 1Q 2023). Revenue: CA$240.8k (up 290% from 1Q 2023). Net loss: CA$566.9k (loss narrowed 44% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.Reported Earnings • Jun 29Full year 2023 earnings released: CA$0.037 loss per share (vs CA$0.085 loss in FY 2022)Full year 2023 results: CA$0.037 loss per share (improved from CA$0.085 loss in FY 2022). Revenue: CA$718.3k (down 59% from FY 2022). Net loss: CA$3.81m (loss narrowed 55% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.공고 • Jun 03Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023.공고 • May 11Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian MarketRapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia.Board Change • May 05High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Mark Upsdell is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • May 27Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced a brokered private placement of 5,000 units at a price of CAD 1,000 per unit for gross proceeds of CAD 5,000,000 on May 27, 2022. Each unit will consist of CAD 1,000 principal amount of unsecured convertible notes and 100 common share purchase warrants. All notes will have a maturity date of 24 months from the closing date and will bear interest from their date of issue at 10.0% per annum, payable quarterly in arrears. A further 2% per annum interest payment will be made annually in cash or in common shares as determined by the company. During the second year of the two-year term of the notes, the company may prepay all or any portion of each of the notes with an early termination fee payable to each noteholder of 1% of the amount of the principal prepayment of the note. The notes will be convertible, at the option of the holders at any time prior to maturity, into common shares at a conversion price of CAD 0.40 per share. Each warrant may be exercised for one common share at a price of CAD 0.40 per share for a term of 24 months from the closing date. All securities issued will be subject to a four month hold from the date of closing.공고 • May 26Rapid Dose Therapeutics Corp. announced a financing transactionRapid Dose Therapeutics Corp. announced a private placement of unit at an issue price of CAD 0.30 per unit on May 25, 2022. Each unit consists of one common share and one common share purchase warrant which entitles the holder to acquire one common share of the company at CAD 0.40 per share. The Share Purchase Warrants expire twenty-four months from the date of issuance. On the same date the company issued 506,157 Common Share Units a for proceeds to CAD 151,847 in its first tranche.Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Chairman of the Board & CEO Mark Upsdell is the most experienced director on the board, commencing their role in 2017. Independent Director Peter-Thilo Hasler was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공고 • Feb 11Rapid Dose Therapeutics Announces Management ChangeRapid Dose Therapeutics Corp. announced a management change in the Company. The Board of Directors provided notice on February 9, 2022 of its intention not to renew Mr. Thomas Bryson’s employment agreement, which expires at the close of business on March 14, 2022. Mr. Bryson joined RDT in March 2021 with the amalgamation of his predecessor company Consolidated Craft Brands Inc. (“CCB”) and assisted in the integration of CCB into RDT within the terms of his one-year employment contract. Mr. Bryson will continue as an employee of RDT until the end of his agreement, but was relieved of all duties and responsibilities as President of RDT at the close of business on February 9, 2022.Reported Earnings • Jan 30Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: CA$0.008 loss per share (down from CA$0.007 loss in 3Q 2021). Revenue: CA$457.7k (up 262% from 3Q 2021). Net loss: CA$790.8k (loss widened 55% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 02Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: CA$324.6k (up CA$321.1k from 2Q 2021). Net loss: CA$539.4k (loss widened 22% from 2Q 2021).Reported Earnings • Aug 30First quarter 2022 earnings released: EPS CA$0.002 (vs CA$0.006 loss in 1Q 2021)First quarter 2022 results: Net income: CA$128.6k (up CA$623.9k from 1Q 2021).공고 • Mar 12Rapid Dose Therapeutics Corp. Signs Production Agreement With OG Laboratories Canada Inc. to Produce Cannabis Vape and CBD From Hemp ProductsRapid Dose Therapeutics Corp. announced that it has entered into a product manufacturing and distribution agreement with OG Laboratories Canada Inc., a wholly owned subsidiary of OG Laboratories LLC. (“OG”) headquartered in Deerfield Beach Florida, to manufacture OG’s vape line of products for the Canadian market. OG will license its formulations, processes, certain technology and provide the equipment to RDT in return for service fees based on sales. OG has experienced rapid growth in the United States creating a premium CBD from hemp line of products marketed through its popular website www.oglaboratories.com. OG has been seeking a Canadian partner who shares the same business vision for its products and has the capability to produce for both the cannabis and non-cannabis sectors in the Canadian marketplace. RDT with its cannabis licence and built out production facility in Burlington Ontario is the perfect fit for establishing OG product sales in Canada. OG’s product line adds to RDT’s growing array of products available to consumers through both the cannabis and nutraceutical distribution channels. With the recently announced acquisition of Consolidated Craft Brands, and through its selling shareholder alliances, these channels are expanding rapidly for products like the ‘QuickStrip™’, nutraceuticals, topicals and now the OG product line.Reported Earnings • Feb 01Third quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.039 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$511.8k (loss narrowed 83% from 3Q 2020).공고 • Jan 12Rapid Dose Therapeutics Corp. (CNSX:DOSE) entered into a binding letter of intent to acquire 2544737 Ontario Limited for $5 million.Rapid Dose Therapeutics Corp. (CNSX:DOSE) entered into a binding letter of intent to acquire 2544737 Ontario Limited for $5 million on January 11, 2021. Pursuant to the transaction, Rapid Dose is to issue 16,666,667 common share units, each consisting of 1 common share and 1 common share purchase warrant at a deemed price of $0.30 per unit in exchange for 100% of the common shares of 2544737 Ontario Limited. The number of common shares of Rapid Dose to be issued represents, after issuance, approximately 17.12% of the issued and outstanding shares of Rapid Dose on an undiluted basis and approximately 27.53% of Rapid Dose shares on a fully diluted basis after taking into consideration the exercise of all stock options and warrants outstanding after this transaction. The transaction is subject to negotiation of a definitive agreement which will contain terms and conditions of the LOI and other terms and conditions customary for transactions of the nature and magnitude of the transaction, including completion of due diligence investigations and any necessary approvals of regulatory authorities, shareholders, and board of directors. The transaction will also be subject to a negotiated escrow agreement between the parties including timed releases of the units over a period of 11 months. The transaction is expected to be completed on February 15, 2021.공고 • Nov 27Rapid Dose Therapeutics Signs Definitive Agreement to Enable Commercial Production of Ultrapure THC Distillate Using RDT's Novel CBD to THC Conversion TechnologyRapid Dose Therapeutics Corp. announced it signed a definitive agreement with ESJ Enterprises, LLC. RDT has licensed ESJ to produce Ultrapure THC (U-THCTM) Delta 9 distillate using the RDT's proprietary CBD to THC conversion technology. In conjunction with the McMaster University research team lead by Drs. James Mcnulty and Alex Nielsen, RDT has developed a process using its Genius Conversion CatalystTM (GCCTM) to transform CBD isolate into THC distillate with a selective Delta 9 or Delta 8 outcome at a rate of 99%. ESJ has worked with RDT to create a scalable process facility that can produce up to 100 kg of Ultrapure THC (U-THCTM) Delta 9 distillate per day. By combining the steady supply of high-quality Isolera Extracts CBD isolate with the RDT GCC process, an unlimited amount of U-THCTM distillate is possible. Production of the first 400 kg of U-THCTM distillate will be completed in Oklahoma prior to December 15, 2020 to fill a backlog of demand in the state. Continuous production of the Ultrapure THC will commence in Michigan in December 2020 to ensure cannabis processors there can meet their market supply requirements.공고 • Oct 05Rapid Dose Therapeutics Amends Agreement with Aphria to Produce in Burlington, Ontario FacilityRapid Dose Therapeutics Corp. announced it has amended the agreement with Aphria Inc. signed Nov. 1, 2018. The amended agreement enables RDT to produce the QuickStrips at its licensed Burlington facility for Aphria. As part of the amendment, Aphria relinquishes its global exclusive preferred vendor status enabling RDT to enter new markets with other licensed producers.공고 • Aug 21Rapid Dose Therapeutics Corp. to Report Q1, 2021 Results on Sep 13, 2020Rapid Dose Therapeutics Corp. announced that they will report Q1, 2021 results on Sep 13, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 DOSE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: DOSE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Rapid Dose Therapeutics 배당 수익률 vs 시장DOSE의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (DOSE)n/a시장 하위 25% (CA)1.6%시장 상위 25% (CA)5.4%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (DOSE) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 DOSE 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 DOSE 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 DOSE 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: DOSE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/25 22:27종가2026/07/23 00:00수익2026/02/28연간 수익2026/02/28데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Rapid Dose Therapeutics Corp.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Peter-Thilo HaslerSphene Capital GmbH
공고 • Jul 13Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 26, 2026Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 26, 2026.
Reported Earnings • Jun 30Full year 2026 earnings released: CA$0.025 loss per share (vs CA$0.043 loss in FY 2025)Full year 2026 results: CA$0.025 loss per share (improved from CA$0.043 loss in FY 2025). Revenue: CA$2.77m (up 33% from FY 2025). Net loss: CA$3.39m (loss narrowed 37% from FY 2025). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
New Risk • Jun 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$871k free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-CA$6.6m). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (CA$13.0m market cap, or US$9.15m). Minor Risk Revenue is less than US$5m (CA$2.8m revenue, or US$2.0m).
New Risk • Mar 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$871k free cash flow). Negative equity (-CA$6.6m). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (CA$13.5m market cap, or US$9.87m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$2.8m revenue, or US$2.0m).
Reported Earnings • Feb 01Third quarter 2026 earnings released: CA$0.009 loss per share (vs CA$0.011 loss in 3Q 2025)Third quarter 2026 results: CA$0.009 loss per share (improved from CA$0.011 loss in 3Q 2025). Revenue: CA$657.1k (up 31% from 3Q 2025). Net loss: CA$1.14m (loss narrowed 16% from 3Q 2025).
New Risk • Jan 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Negative equity (-CA$5.9m). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$2.6m revenue, or US$1.9m). Market cap is less than US$100m (CA$19.0m market cap, or US$13.7m).
Reported Earnings • Nov 02Second quarter 2026 earnings released: EPS: CA$0.01 (vs CA$0.009 loss in 2Q 2025)Second quarter 2026 results: EPS: CA$0.01 (up from CA$0.009 loss in 2Q 2025). Revenue: CA$672.9k (up 30% from 2Q 2025). Net loss: CA$825.5k (loss narrowed 25% from 2Q 2025).
New Risk • Jul 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$965k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$965k free cash flow). Negative equity (-CA$5.3m). Earnings have declined by 6.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (CA$2.5m revenue, or US$1.8m). Market cap is less than US$100m (CA$25.2m market cap, or US$18.3m).
Reported Earnings • Jul 29First quarter 2026 earnings released: CA$0.006 loss per share (vs CA$0.01 loss in 1Q 2025)First quarter 2026 results: CA$0.006 loss per share (improved from CA$0.01 loss in 1Q 2025). Revenue: CA$782.7k (up 96% from 1Q 2025). Net loss: CA$723.7k (loss narrowed 42% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.043 loss per share (vs CA$0.041 loss in FY 2024)Full year 2025 results: CA$0.043 loss per share (further deteriorated from CA$0.041 loss in FY 2024). Revenue: CA$2.09m (up 104% from FY 2024). Net loss: CA$5.40m (loss widened 26% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
공고 • Jun 30Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025.
공고 • May 28Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in fundingRapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.
공고 • May 27Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery TechnologyRapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.
New Risk • Mar 04New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$4.1m). Minor Risks Revenue is less than US$5m (CA$1.6m revenue, or US$1.1m). Market cap is less than US$100m (CA$21.8m market cap, or US$15.0m).
공고 • Feb 19Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.
Reported Earnings • Jan 29Third quarter 2025 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 3Q 2024). Revenue: CA$501.7k (up 115% from 3Q 2024). Net loss: CA$1.36m (loss widened 39% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공고 • Dec 11Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share.
Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2024)Second quarter 2025 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2024). Revenue: CA$515.9k (up 46% from 2Q 2024). Net loss: CA$1.10m (loss widened 51% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
공고 • Oct 31+ 1 more updateRapid Dose Therapeutics Corp. announced that it has received CAD 0.548799 million in funding from Madison Partners CorporationOn October 30, 2024. the company has closed the final tranche of the transaction
분석 기사 • Aug 22This Is Why Rapid Dose Therapeutics Corp.'s (CSE:DOSE) CEO Compensation Looks AppropriateKey Insights Rapid Dose Therapeutics' Annual General Meeting to take place on 28th of August Total pay for CEO Mark...
New Risk • Jul 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.8m free cash flow). Negative equity (-CA$3.3m). Revenue is less than US$1m (CA$1.2m revenue, or US$852k). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$22.4m market cap, or US$16.2m).
Reported Earnings • Jun 30Full year 2024 earnings released: CA$0.041 loss per share (vs CA$0.037 loss in FY 2023)Full year 2024 results: CA$0.041 loss per share (further deteriorated from CA$0.037 loss in FY 2023). Revenue: CA$1.02m (up 42% from FY 2023). Net loss: CA$4.31m (loss widened 13% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
공고 • Jun 27Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024.
공고 • Mar 26Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing.
Reported Earnings • Jan 30Third quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in 3Q 2023). Revenue: CA$233.8k (down 24% from 3Q 2023). Net loss: CA$981.1k (loss widened 68% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
공고 • Jan 20Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in fundingRapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent.
New Risk • Jan 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$524k free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-CA$3.8m). Revenue is less than US$1m (CA$1.1m revenue, or US$826k). Minor Risks Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Market cap is less than US$100m (CA$18.0m market cap, or US$13.3m).
Reported Earnings • Oct 31Second quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in 2Q 2023)Second quarter 2024 results: CA$0.007 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$353.2k (up 164% from 2Q 2023). Net loss: CA$730.7k (loss narrowed 20% from 2Q 2023).
공고 • Sep 23Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of DirectorsRapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023.
New Risk • Aug 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$3.2m). Revenue is less than US$1m (CA$897k revenue, or US$663k). Market cap is less than US$10m (CA$13.5m market cap, or US$9.95m).
Reported Earnings • Jul 31First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.01 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.01 loss in 1Q 2023). Revenue: CA$240.8k (up 290% from 1Q 2023). Net loss: CA$566.9k (loss narrowed 44% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Jun 29Full year 2023 earnings released: CA$0.037 loss per share (vs CA$0.085 loss in FY 2022)Full year 2023 results: CA$0.037 loss per share (improved from CA$0.085 loss in FY 2022). Revenue: CA$718.3k (down 59% from FY 2022). Net loss: CA$3.81m (loss narrowed 55% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
공고 • Jun 03Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023.
공고 • May 11Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian MarketRapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia.
Board Change • May 05High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Mark Upsdell is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • May 27Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced a brokered private placement of 5,000 units at a price of CAD 1,000 per unit for gross proceeds of CAD 5,000,000 on May 27, 2022. Each unit will consist of CAD 1,000 principal amount of unsecured convertible notes and 100 common share purchase warrants. All notes will have a maturity date of 24 months from the closing date and will bear interest from their date of issue at 10.0% per annum, payable quarterly in arrears. A further 2% per annum interest payment will be made annually in cash or in common shares as determined by the company. During the second year of the two-year term of the notes, the company may prepay all or any portion of each of the notes with an early termination fee payable to each noteholder of 1% of the amount of the principal prepayment of the note. The notes will be convertible, at the option of the holders at any time prior to maturity, into common shares at a conversion price of CAD 0.40 per share. Each warrant may be exercised for one common share at a price of CAD 0.40 per share for a term of 24 months from the closing date. All securities issued will be subject to a four month hold from the date of closing.
공고 • May 26Rapid Dose Therapeutics Corp. announced a financing transactionRapid Dose Therapeutics Corp. announced a private placement of unit at an issue price of CAD 0.30 per unit on May 25, 2022. Each unit consists of one common share and one common share purchase warrant which entitles the holder to acquire one common share of the company at CAD 0.40 per share. The Share Purchase Warrants expire twenty-four months from the date of issuance. On the same date the company issued 506,157 Common Share Units a for proceeds to CAD 151,847 in its first tranche.
Board Change • Apr 27Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Chairman of the Board & CEO Mark Upsdell is the most experienced director on the board, commencing their role in 2017. Independent Director Peter-Thilo Hasler was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공고 • Feb 11Rapid Dose Therapeutics Announces Management ChangeRapid Dose Therapeutics Corp. announced a management change in the Company. The Board of Directors provided notice on February 9, 2022 of its intention not to renew Mr. Thomas Bryson’s employment agreement, which expires at the close of business on March 14, 2022. Mr. Bryson joined RDT in March 2021 with the amalgamation of his predecessor company Consolidated Craft Brands Inc. (“CCB”) and assisted in the integration of CCB into RDT within the terms of his one-year employment contract. Mr. Bryson will continue as an employee of RDT until the end of his agreement, but was relieved of all duties and responsibilities as President of RDT at the close of business on February 9, 2022.
Reported Earnings • Jan 30Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: CA$0.008 loss per share (down from CA$0.007 loss in 3Q 2021). Revenue: CA$457.7k (up 262% from 3Q 2021). Net loss: CA$790.8k (loss widened 55% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 02Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: CA$324.6k (up CA$321.1k from 2Q 2021). Net loss: CA$539.4k (loss widened 22% from 2Q 2021).
Reported Earnings • Aug 30First quarter 2022 earnings released: EPS CA$0.002 (vs CA$0.006 loss in 1Q 2021)First quarter 2022 results: Net income: CA$128.6k (up CA$623.9k from 1Q 2021).
공고 • Mar 12Rapid Dose Therapeutics Corp. Signs Production Agreement With OG Laboratories Canada Inc. to Produce Cannabis Vape and CBD From Hemp ProductsRapid Dose Therapeutics Corp. announced that it has entered into a product manufacturing and distribution agreement with OG Laboratories Canada Inc., a wholly owned subsidiary of OG Laboratories LLC. (“OG”) headquartered in Deerfield Beach Florida, to manufacture OG’s vape line of products for the Canadian market. OG will license its formulations, processes, certain technology and provide the equipment to RDT in return for service fees based on sales. OG has experienced rapid growth in the United States creating a premium CBD from hemp line of products marketed through its popular website www.oglaboratories.com. OG has been seeking a Canadian partner who shares the same business vision for its products and has the capability to produce for both the cannabis and non-cannabis sectors in the Canadian marketplace. RDT with its cannabis licence and built out production facility in Burlington Ontario is the perfect fit for establishing OG product sales in Canada. OG’s product line adds to RDT’s growing array of products available to consumers through both the cannabis and nutraceutical distribution channels. With the recently announced acquisition of Consolidated Craft Brands, and through its selling shareholder alliances, these channels are expanding rapidly for products like the ‘QuickStrip™’, nutraceuticals, topicals and now the OG product line.
Reported Earnings • Feb 01Third quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.039 loss in 3Q 2020)Third quarter 2021 results: Net loss: CA$511.8k (loss narrowed 83% from 3Q 2020).
공고 • Jan 12Rapid Dose Therapeutics Corp. (CNSX:DOSE) entered into a binding letter of intent to acquire 2544737 Ontario Limited for $5 million.Rapid Dose Therapeutics Corp. (CNSX:DOSE) entered into a binding letter of intent to acquire 2544737 Ontario Limited for $5 million on January 11, 2021. Pursuant to the transaction, Rapid Dose is to issue 16,666,667 common share units, each consisting of 1 common share and 1 common share purchase warrant at a deemed price of $0.30 per unit in exchange for 100% of the common shares of 2544737 Ontario Limited. The number of common shares of Rapid Dose to be issued represents, after issuance, approximately 17.12% of the issued and outstanding shares of Rapid Dose on an undiluted basis and approximately 27.53% of Rapid Dose shares on a fully diluted basis after taking into consideration the exercise of all stock options and warrants outstanding after this transaction. The transaction is subject to negotiation of a definitive agreement which will contain terms and conditions of the LOI and other terms and conditions customary for transactions of the nature and magnitude of the transaction, including completion of due diligence investigations and any necessary approvals of regulatory authorities, shareholders, and board of directors. The transaction will also be subject to a negotiated escrow agreement between the parties including timed releases of the units over a period of 11 months. The transaction is expected to be completed on February 15, 2021.
공고 • Nov 27Rapid Dose Therapeutics Signs Definitive Agreement to Enable Commercial Production of Ultrapure THC Distillate Using RDT's Novel CBD to THC Conversion TechnologyRapid Dose Therapeutics Corp. announced it signed a definitive agreement with ESJ Enterprises, LLC. RDT has licensed ESJ to produce Ultrapure THC (U-THCTM) Delta 9 distillate using the RDT's proprietary CBD to THC conversion technology. In conjunction with the McMaster University research team lead by Drs. James Mcnulty and Alex Nielsen, RDT has developed a process using its Genius Conversion CatalystTM (GCCTM) to transform CBD isolate into THC distillate with a selective Delta 9 or Delta 8 outcome at a rate of 99%. ESJ has worked with RDT to create a scalable process facility that can produce up to 100 kg of Ultrapure THC (U-THCTM) Delta 9 distillate per day. By combining the steady supply of high-quality Isolera Extracts CBD isolate with the RDT GCC process, an unlimited amount of U-THCTM distillate is possible. Production of the first 400 kg of U-THCTM distillate will be completed in Oklahoma prior to December 15, 2020 to fill a backlog of demand in the state. Continuous production of the Ultrapure THC will commence in Michigan in December 2020 to ensure cannabis processors there can meet their market supply requirements.
공고 • Oct 05Rapid Dose Therapeutics Amends Agreement with Aphria to Produce in Burlington, Ontario FacilityRapid Dose Therapeutics Corp. announced it has amended the agreement with Aphria Inc. signed Nov. 1, 2018. The amended agreement enables RDT to produce the QuickStrips at its licensed Burlington facility for Aphria. As part of the amendment, Aphria relinquishes its global exclusive preferred vendor status enabling RDT to enter new markets with other licensed producers.
공고 • Aug 21Rapid Dose Therapeutics Corp. to Report Q1, 2021 Results on Sep 13, 2020Rapid Dose Therapeutics Corp. announced that they will report Q1, 2021 results on Sep 13, 2020